Page last updated: 2024-11-07

vb 20b7

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(1-(4-piperonyl)piperazinyl)benzothiazole: a 5-HT3 receptor antagonist and 5-HT4 receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127902
CHEMBL ID24909
CHEBI ID113557
SCHEMBL ID677470
MeSH IDM0230850

Synonyms (44)

Synonym
2-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzothiazole
bdbm50041377
HMS3266N21
BRD-K91868854-001-01-0
BPBIO1_000397
OPREA1_318218
tocris-0736
NCGC00024757-01
BIOMOL-NT_000145
NCGC00024757-02
2-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)benzothiazole
vb 20b7
2-ppbt
benzothiazole, 2-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-
2-(1-(4-piperonyl)piperazinyl)benzothiazole
OPREA1_123424
L011434
CHEBI:113557
CHEMBL24909 ,
155106-73-3
vb20b7
vb-20b7
ppb benzothiazole
2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-1,3-benzothiazole
2-[1-(4-piperonyl)piperazinyl]benzothiazole
c19h19n3o2s
SCHEMBL677470
Z86248421
AKOS024458622
2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)benzo[d]thiazole
F5773-3525
Q27194452
DTXSID30165813
SR-01000597727-1
sr-01000597727
J-009170
2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1,3-benzothiazole
HMS3675F07
HMS3411F07
BRD-K91868854-001-02-8
benzothiazole, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-
CS-0012004
EN300-6493077
2-{4-[(1,3-dioxaindan-5-yl)methyl]piperazin-1-yl}-1,3-benzothiazole
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-arylpiperazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency100.00000.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency1.25890.031637.5844354.8130AID504865
regulator of G-protein signaling 4Homo sapiens (human)Potency0.10620.531815.435837.6858AID504845
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency39.81070.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.63100.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.94330.00636.904339.8107AID883
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency7.07950.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.63100.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)100.00000.00031.38338.4000AID3179
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00051.48357.8000AID3179
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00311.73607.8000AID3179
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00501.79627.8000AID3179
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)0.95000.00021.13514.6000AID6077
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.54948.4000AID64612
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)0.95000.00041.17424.6000AID6077
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID79191The compound was evaluated for the percentage inhibition in guinea pig ileum stimulated with 10 uM 5-HT and tested at fixed concentration of 10 uM1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID184268The compound was evaluated for the percentage increase in gastric emptying for a dose of 7.5 mg/kg perorally in rat.1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID195207The compound was evaluated for the percentage inhibition in rat aorta stimulated with 30 uM 5-HT and tested at fixed concentration of 10 uM1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID230155The compound was evaluated for equipotent concentration ratio (ECR). whereECR = IC40 test agonist / IC40 5-HT1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID3179Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID6077Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID186653The compound was evaluated for the intrinsic activity in rat isolated esophageal tunica muscularis mucose1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID184264The compound was evaluated for the percentage increase in gastric emptying for a dose of 10 mg/kg perorally in rat.1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID64612Displacement of [3H]spiroperidol from D2 dopamine receptor1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID197348Agonist potency in rat isolated esophageal tunica muscularis mucose.1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID79380The compound was evaluated for the pA2 value that was estimated using 2-methyl-5-HT in five to seven different tissues in guinea pig ileum1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID6088Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID184266The compound was evaluated for the percentage increase in gastric emptying for a dose of 5 mg/kg perorally in rat.1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.77 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]